10 reports

  • 6 Current Treatment Options
  • 8 Research and Development Strategies

MEDIAN NUMBER OF TREATMENT CYCLES WAS ##. ## (RANGE ##-##+).

  • Chemotherapy
  • Hospital
  • Leukemia
  • Therapy
  • Astex Pharmaceuticals, Inc.
  • AT-13148 - DRUG PROFILE

By targeting cancer cells at a range of weak spots instead of just one, tumors will be less likely to develop resistance to this treatment.

  • Pharmaceutical
  • Specialty Hospital
  • Therapy
  • Product Initiative
  • Astex Pharmaceuticals, Inc.
  • Pipeline portfolio

It is one of the most popular therapies for treating individuals with myelodysplastic syndrome who are at risk of acute myeloid leukemia.

  • Therapy
  • Demand
  • Market Segment
  • Market Size
  • Astex Pharmaceuticals, Inc.
  • Astex Pharmaceuticals Inc, Deals By Therapy Area, 2012 to YTD 2018
  • OCT 26, 2017: STUDY TO TEST COMBINATION THERAPY FOR BREAST CANCER

Swisher, MD, University of Washington$## million.

  • Healthcare
  • Pharmaceutical
  • Therapy
  • United States
  • Astex Pharmaceuticals, Inc.
  • ASTEX PHARMACEUTICALS INC
  • SENTINEL ONCOLOGY LIMITED

By targeting cancer cells at a range of weak spots instead of just one, tumors will be less likely to develop resistance to this treatment.

  • Cancer
  • Hospital
  • Specialty Hospital
  • Therapy
  • Astex Pharmaceuticals, Inc.
  • ASTEX PHARMACEUTICALS, INC.
  • SENTINEL ONCOLOGY LIMITED

By targeting cancer cells at a range of weak spots instead of just one, tumors will be less likely to develop resistance to this treatment.

  • Cancer
  • Pharmaceutical
  • Specialty Hospital
  • Therapy
  • Astex Pharmaceuticals, Inc.
  • Pipeline by Astex Pharmaceuticals, Inc., H1 2016
  • AT-13148 - Drug Profile

By targeting cancer cells at a range of weak spots instead of just one, tumors will be less likely to develop resistance to this treatment.

  • Pharmaceutical
  • Specialty Hospital
  • Therapy
  • United Kingdom
  • Astex Pharmaceuticals, Inc.
  • onalespib

In part two, patients will be randomized to receive the dose identified in Part one plus carboplatin or one of three treatment of choice at the discretion of the investigator.

  • Pharmaceutical
  • Therapy
  • United States
  • Company Operations
  • Astex Pharmaceuticals, Inc.
  • OF CONTENTS
  • OF CONTENTS

Pharmaceuticals and Healthcare--> Pharmaceuticals-- > Pharmaceutical Manufacturers Pharmaceuticals and Healthcare--> Therapy Area--> Central Nervous System Pharmaceuticals and Healthcare--> Therapy Area--> Infectious Diseases Pharmaceuticals and Healthcare-->

  • Therapy
  • United Kingdom
  • Corporate Finance
  • Deals & Alliance
  • Astex Pharmaceuticals, Inc.
  • PARTNER 1: ASTEX THERAPEUTICS LIMITED
  • ASTEX PHARMACEUTICALS, INC. (FORMERLY SUPERGEN, INC.)

PARTNER ## ASTEX PHARMACEUTICALS, INC.

  • Therapy
  • United Kingdom
  • Company
  • M&A
  • Astex Pharmaceuticals, Inc.